AzTrials
AzTrials

Cervical Cancer Stage IIIBNCT03477240

Feasibility Study Of A Telephonic Questionnaire For Follow-Up Of Locally Advanced Cervical Cancer Patients

An observational study of Cervical Cancer Stage IIIB and Treatment Outcome, run by Tata Memorial Hospital.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Cross-sectional Feasibility study on all consecutive patients of locally advanced cancer of the cervix or vault treated entirely at Tata Memorial Centre with curative intent radiation or chemoradiation. Read more about this study

Who is it for?
Any age, women only
How many people
300 participants
Where
No sites listed yet
Study dates
1 May 2018to 1 Aug 2019
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • Women only
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: All consecutive patients of locally advanced cancer of the cervix or vault treated entirely at Tata Memorial Centre with curative intent radiation or chemoradiation.

Who may be able to join

  • Cervical Cancer Stage Ib2, II and III (Squamous carcinoma or adenocarcinoma)
  • Cancer of the vault
  • Cancer of the cervix which inadvertently underwent hysterectomy (inadequate surgery)
  • Treated with curative intent with radical radio(chemo)therapy or NACT followed by radical radio(chemo)therapy and completed all curative treatment.
  • Within 2 years post completion of treatment
  • Has complete clinical response at 3 months post treatment
  • Informed consent
  • Contactable by telephone

Who cannot join

  • Patients with Stage III disease treated with palliative intent with once monthly radiotherapy
  • Early stage cervical cancer patients who underwent Wertheims hysterectomy and who have completed adjuvant radiochemotherapy due to high-risk factors
  • Metastatic cervical cancers
  • Patients who are unable to comprehend the questions or dialogue over telephone by medical staff.
  • Patients who seem unreliable for follow up

About this study

Official title: A Cross-Sectional Feasibility Study of a Telephonic Questionnaire By Research Nurses For Follow-Up Of Locally Advanced Cervical Cancer Patients With Complete Response To Treatment.

Cross-sectional Feasibility study on all consecutive patients of locally advanced cancer of the cervix or vault treated entirely at Tata Memorial Centre with curative intent radiation or chemoradiation.

Read the detailed description

Our institution registers on an average 670 cases of cancer cervix in a year and almost 75% are treated with curative intent, therefore around 500 patients a year would be treated with curative intent. Assuming that 75% of patients registered in a year would be receiving treatment at our institute, 375 patients a year would be completing treatment, of whom the investigator expect 80-85% ,i.e 300 patients to have a complete response. The list of patients who have completed radio(chemotherapy) in 2015 \&2016 can be obtained from the Radiation Oncology Department records. Patients identified for a follow up visit will be telephonically contacted between one and two weeks before the planned clinic visit and verbal telephonic consent taken prior to the nurse-led interview. This study should be able to accrue 300 patients in 6 months.

Patients of locally advanced cervical cancer or vault cancer who have been treated with radiotherapy with or without concurrent chemotherapy and have a clinical complete response at 3 months post treatment and are within the first 2 years post treatment completion will be eligible to participate in this study.

Screening: Patients will be screened from the list of patients treated in the radiotherapy department over the last 2 years (2015-2016), available from the Radiation Oncology Information System (ROIS). All patients with a diagnosis of cervical cancer or vault cancer will be screened using the hospital Electronic Medical Record (EMR) to check stage of disease, schedule of treatment received, response at 3 months post treatment and expected date of next follow up.

If patient fulfils all inclusion criteria, she will be called by the research nurse, approximately 1-2 weeks prior to her expected date of follow up, for a preliminary conversation and invited to participate in the study.

After verbal telephonic consent is obtained, she will be interviewed by the clinical research nurse using the format of the prepared proforma (Form A) regarding symptoms suggestive of disease recurrence as well as treatment induced toxicity. At the end of the interview, the research nurse records her impression of whether the patient has worrisome symptoms of disease or not and has symptoms of treatment toxicity or not for which she should visit the hospital.

When the patient reports to the OPD the next week for scheduled physical follow up, the nurse completes the consenting process by taking a short written informed consent. The examining physician then takes a complete history and in addition, performs a physical examination and any investigations he/she deems necessary. Following this he/she notes down final impression of disease status and toxicity which are taken as the gold standard (Form B). Each patient will be interviewed only once during their follow up schedule.

In addition at the physical visit, information regarding the acceptability of nurse-led telephonic follow-up to the patient and the financial impact of physical follow- up will be collected using a structured format (Form C).

Study participant drop-out/ Lost-to-follow up: Patients may withdraw their consent at any point during the telephonic interview or the subsequent follow up visit.

  • A patient who does not attend the scheduled follow up visit within 1-2 weeks of the telephonic interview will be called a second time to remind her of the follow up appointment and enquire about reasons for non-attendance in the clinic, which will be recorded. If patient does not report to the clinic within the next 2 weeks, she will be considered to have dropped out from the study.
  • Those patients in whom the interval between telephonic interview and the physician's assessment is more than 4 weeks, will be considered drop outs and follow up telephone call will go out to enquire about reasons for non-attendance in the clinic, which will be recorded.
Keywords
Cervical Cancer, TELEPHONIC QUESTIONNAIRE, Follow up
Medical subject headings
Uterine Cervical Neoplasms

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Accuracy of nurse-led telephonic interview for disease recurrence

    To estimate the accuracy of nurse-led telephonic interview in identifying patients with symptoms suggestive of disease recurrence, in terms of sensitivity and specificity values

    Measured: 1 YEAR

Secondary outcomes (2)
  1. Accuracy of nurse-led telephonic interview for late toxicity of treatment

    To estimate the accuracy of nurse-led telephonic interview in identifying patients with symptoms suggestive of late toxicity of treatment

    Measured: 1 YEAR

  2. Acceptability of a nurse-led telephonic surveillance program using structured format (Form C).

    To assess patients' acceptability of a nurse-led telephonic surveillance program (if found to be concordant with physical clinic visits)

    Measured: 1 YEAR

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Mar 2018
  2. Study start1 May 2018 (estimated)
  3. Primary completion28 Feb 2019 (estimated)
  4. Study completion1 Aug 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Cross-sectional
Enrolment
300 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03477240
Sponsor's protocol ID
TMH-1950
Status last verified
Feb 2018
First submitted
11 Jan 2018
Last updated
26 Mar 2018
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: No IPD will be shared

Questions about this trial

What is this clinical trial studying?

An observational study of Cervical Cancer Stage IIIB and Treatment Outcome, run by Tata Memorial Hospital.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 26 Mar 2018. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Accuracy of nurse-led telephonic interview for disease recurrence (time frame: 1 YEAR). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Mar 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in